Takeda signs option deal for MacroGenics bi-specific antibody
This article was originally published in Scrip
Executive Summary
Takeda Pharmaceutical will pay MacroGenics $15m up front for an option to license the early-stage bi-specific antibody MGD010 for autoimmune diseases in an agreement worth up to $501.5m plus royalties.